Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors (excluding primary CNS tumors) who have progressed on or are intolerant to standard therapies, with preferential inclusion of BRCA2 loss-of-function cases. Patients receive ETX-19477, a novel reversible small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), given as monotherapy.
ClinicalTrials.gov ID: NCT06395519
HealthScout AI summary: This trial enrolls adults with advanced breast cancer whose disease has progressed after all standard therapies, treating them with oral MBQ-167, a novel dual inhibitor of the Rho GTPases Rac and Cdc42. Patients must be able to swallow oral medication, have adequate organ function, and may have stable, asymptomatic brain metastases.
ClinicalTrials.gov ID: NCT06075810
HealthScout AI summary: This trial enrolls adults and adolescents (≥12 years, ≥40 kg) with advanced or metastatic solid tumors refractory to standard therapy—including dedicated cohorts for TNBC, SCLC, and tumors with RB1 alteration—for treatment with CID-078, a first-in-class oral macrocyclic inhibitor that blocks cyclin A/B-RxL interactions to induce cell cycle arrest. All patients receive CID-078 monotherapy in 21-day cycles.
ClinicalTrials.gov ID: NCT06577987
HealthScout AI summary: This trial enrolls adults with metastatic pancreatic (ductal or acinar) or HER2-negative breast cancer harboring BRCA1, BRCA2, or PALB2 mutations, and treats them with high-dose melphalan and BCNU in combination with vitamin B12b, escalating doses of vitamin C, and low-dose ethanol, followed by autologous hematopoietic stem cell rescue. The investigational regimen aims to overcome drug resistance in homologous recombination-deficient tumors by exploiting oxidative stress pathways.
ClinicalTrials.gov ID: NCT04150042
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring homologous recombination deficiency (HRD), investigating the safety and activity of the investigational oral polymerase theta (Polθ) helicase inhibitor MOMA-313 as monotherapy or in combination with the PARP inhibitor olaparib. Eligible combination therapy patients include those with metastatic prostate, breast, or pancreatic cancer and must be PARP inhibitor naive.
ClinicalTrials.gov ID: NCT06545942
HealthScout AI summary: This trial enrolls adults with advanced, measurable solid tumors (including NSCLC and head and neck squamous cell carcinoma), evaluating intravenous TUB-030, an antibody-drug conjugate targeting the 5T4 oncofetal antigen and delivering a topoisomerase I inhibitor, in patients with ECOG 0-1 and adequate organ function. Patients may have clinically stable brain metastases and must have completed prior therapies.
ClinicalTrials.gov ID: NCT06657222
HealthScout AI summary: This trial enrolls adults with advanced hormone receptor-positive, HER2-negative breast cancer who have progressed on prior endocrine therapy and CDK4/6 inhibitors, as well as those with advanced solid tumors harboring CCNE1 amplification, and investigates the investigational agent ECI830 (mechanism not publicly disclosed) given alone or with ribociclib and fulvestrant.
ClinicalTrials.gov ID: NCT06726148
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HER2-negative metastatic breast cancer, mCRPC, advanced pancreatic cancer, and platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer—who have progressed after standard therapy. Patients receive NUV-1511, an investigational drug-drug conjugate designed to selectively deliver a cytotoxic payload to tumor cells to enhance efficacy and limit systemic toxicity.
ClinicalTrials.gov ID: NCT06334432
HealthScout AI summary: This trial enrolls adults with advanced, incurable breast cancer who have progressed after at least one line of endocrine therapy (including prior CDK4/6 inhibitor plus fulvestrant or aromatase inhibitor), testing the KAT6A/B inhibitor MEN2312 as monotherapy and in combination with the oral SERD elacestrant. Prior chemotherapy and antibody-drug conjugates are permitted, but patients with new/active brain metastases or severe organ involvement are excluded.
ClinicalTrials.gov ID: NCT06638307
HealthScout AI summary: This trial enrolls postmenopausal women with advanced or metastatic ER-positive, HER2-negative breast cancer who have progressed on prior endocrine therapy and no more than one chemotherapy for advanced disease, to receive oral AND019, an investigational selective estrogen receptor degrader (SERD) targeting the estrogen receptor. The study focuses on evaluating the safety and early activity of AND019 as monotherapy.
ClinicalTrials.gov ID: NCT05187832
